Patent · US Active

Tandem diabody for CD16A-directed NK-cell engagement

US12264198B2 · kind B2 · utility

0Cited by
1References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 26, 2021
Grant dateApr 1, 2025
Priority date
Expiry dateJul 29, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.